• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

碳青霉烯类耐药肺炎克雷伯菌治疗期间KPC-230介导的对头孢他啶-阿维巴坦耐药性的动态演变

Dynamic evolution of KPC-230-mediated resistance to ceftazidime-avibactam during the treatment of carbapenem-resistant Klebsiella pnenmoniae.

作者信息

Li Xi, Zhou Longjie, Huang Huaqiong

机构信息

Laboratory Medicine Center, Department of Clinical Laboratory, Zhejiang Provincial People's Hospital, Affiliated People's Hospital, Hangzhou Medical College, Hangzhou, Zhejiang 310014, China.

Key Laboratory of Respiratory Disease of Zhejiang Province, Department of Respiratory and Critical Care Medicine, Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, Zhejiang 310009, China.

出版信息

Drug Resist Updat. 2025 Mar;79:101205. doi: 10.1016/j.drup.2025.101205. Epub 2025 Jan 25.

DOI:10.1016/j.drup.2025.101205
PMID:39889330
Abstract

The molecular mechanisms driving the development of KPC-230-mediated resistance to ceftazidime-avibactam during treatment of carbapenem-resistant Klebsiella pneumoniae infection was elucidated by analyzing specimens collected from a patient, including one bla-positive and three bla-positive Klebsiella pnenmoniae isolates.

摘要

通过分析从一名患者收集的标本,包括一株bla阳性和三株bla阳性肺炎克雷伯菌分离株,阐明了在耐碳青霉烯类肺炎克雷伯菌感染治疗期间,KPC - 230介导的对头孢他啶 - 阿维巴坦耐药性发展的分子机制。

相似文献

1
Dynamic evolution of KPC-230-mediated resistance to ceftazidime-avibactam during the treatment of carbapenem-resistant Klebsiella pnenmoniae.碳青霉烯类耐药肺炎克雷伯菌治疗期间KPC-230介导的对头孢他啶-阿维巴坦耐药性的动态演变
Drug Resist Updat. 2025 Mar;79:101205. doi: 10.1016/j.drup.2025.101205. Epub 2025 Jan 25.
2
Evolution of ceftazidime-avibactam resistance driven by mutations in double-copy to during treatment of ST11 carbapenem-resistant .治疗 ST11 碳青霉烯类耐药肠杆菌科细菌时,由于双拷贝到的突变导致头孢他啶-阿维巴坦耐药性的进化。
mSystems. 2024 Oct 22;9(10):e0072224. doi: 10.1128/msystems.00722-24. Epub 2024 Sep 17.
3
Carbapenem-resistant infections in Chinese children: activities of ceftazidime-avibactam and aztreonam-avibactam against carbapenemase-producing strains in a two-center study.中国儿童碳青霉烯类耐药感染:头孢他啶-阿维巴坦和氨曲南-阿维巴坦对产碳青霉烯酶菌株活性的双中心研究
Front Cell Infect Microbiol. 2025 Mar 26;15:1545999. doi: 10.3389/fcimb.2025.1545999. eCollection 2025.
4
In vivo evolution of resistant subpopulations of KPC-producing Klebsiella pneumoniae during ceftazidime/avibactam treatment.产 KPC 肺炎克雷伯菌在头孢他啶/阿维巴坦治疗期间耐药亚群的体内进化。
J Antimicrob Chemother. 2018 Jun 1;73(6):1525-1529. doi: 10.1093/jac/dky082.
5
Overexpression of KPC contributes to ceftazidime-avibactam heteroresistance in clinical isolates of carbapenem-resistant .KPC的过表达导致耐碳青霉烯类临床分离株对头孢他啶-阿维巴坦产生异质性耐药。
Front Cell Infect Microbiol. 2024 Dec 6;14:1450530. doi: 10.3389/fcimb.2024.1450530. eCollection 2024.
6
Molecular Mechanisms Driving the Development of KPC-71-Mediated Resistance to Ceftazidime-Avibactam during Treatment of Carbapenem-Resistant Klebsiella pneumoniae Infections.KPC-71 介导的对头孢他啶-阿维巴坦耐药性发展的分子机制在治疗碳青霉烯类耐药肺炎克雷伯菌感染中的作用。
mSphere. 2021 Dec 22;6(6):e0085921. doi: 10.1128/mSphere.00859-21.
7
Molecular analysis of clinical isolates of ceftazidime-avibactam-resistant Klebsiella pneumoniae.头孢他啶-阿维巴坦耐药肺炎克雷伯菌临床分离株的分子分析。
Clin Microbiol Infect. 2021 Jul;27(7):1040.e1-1040.e6. doi: 10.1016/j.cmi.2021.03.001. Epub 2021 Mar 26.
8
Emergence of ceftazidime-avibactam resistance in bla-harbouring ST11 Klebsiella pneumoniae in a paediatric patient.产碳青霉烯酶肺炎克雷伯菌中 bla harbouring ST11 儿科患者出现头孢他啶-阿维巴坦耐药性。
Int J Antimicrob Agents. 2024 Jun;63(6):107163. doi: 10.1016/j.ijantimicag.2024.107163. Epub 2024 Apr 1.
9
Emergence of ceftazidime/avibactam resistance in carbapenem-resistant Klebsiella pneumoniae in China.中国耐碳青霉烯类肺炎克雷伯菌中头孢他啶/阿维巴坦耐药的出现。
Clin Microbiol Infect. 2020 Jan;26(1):124.e1-124.e4. doi: 10.1016/j.cmi.2019.08.020. Epub 2019 Sep 5.
10
Evolution of Under the Pressure of Carbapenems and Ceftazidime/Avibactam in a Patient With Persistent Bacteremia Caused by .碳青霉烯类和头孢他啶/阿维巴坦压力下导致持续菌血症的 患者的演变。
J Korean Med Sci. 2024 Jul 1;39(25):e208. doi: 10.3346/jkms.2024.39.e208.